Virtual screening of phytoconstituents from miracle herb nigella sativa targeting nucleocapsid protein and papain-like protease of SARS-CoV-2 for COVID-19 treatment

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel etiological agent of coronavirus disease 2019 (COVID-19). Nigella sativa, commonly known as black seed or black cumin, has been a historical and traditional plant since thousands of years. Based on their therapeutic efficacy, the chief components of terpenoids and flavonoids were selected from N. sativa seeds and seed oil. This study was designed to check the antiviral efficacy of N. sativa main phytoconstituents against five potential targets of SARS-CoV-2 using in silico structure-based virtual screening approach. Out of twenty five phytocomponents, ten components showed best binding affinity against two viral proteins viz. N-terminal RNA binding domain (NRBD; PDB ID: 6M3M) of nucleocapsid protein and papain-like protease (PL-(PRO); PDB ID: 6W9C) of SARS-CoV-2 using AutoDock 4.2.6, AutoDock Vina and iGEMDOCK. PASS analyses of all ten phytocomponents using Lipinski's Rule of five showed promising results. Further, druglikeness and toxicity assessment using OSIRIS Data Warrior v5.2.1 software exhibited the feasibility of phytocomponents as drug candidates with no predicted toxicity. Molecular dynamics simulation study of NRBD of SARS-CoV-2 nucleocapsid protein-alpha-spinasterol complex and PL-(PRO)-cycloeucalenol complex displayed strong stability at 300 K. Both these complexes exhibited constant root mean square deviation (RMSDs) of protein side chains and C alpha atoms throughout the simulation run time. Interestingly, PL-(PRO) and NRBD are key proteins in viral replication, host cell immune evasion and viral assembly. Thus, NRBD and PL-(PRO) have the potential to serve as therapeutic targets for N. sativa phytoconstituents in drug discovery process against COVID-19. [GRAPHICS] .

Automated summary

This study investigated the antiviral efficacy of N. sativa main phytoconstituents against SARS-CoV-2 using a computer-based screening approach. Ten components showed the best binding affinity, and subsequent testing demonstrated their feasibility as drug candidates with no predicted toxicity. Molecular dynamics simulations showed that these components formed stable complexes with key viral proteins. Therefore, N. sativa phytoconstituents have the potential to serve as therapeutic targets for COVID-19.